Randomized Phase 2 Study: Neoadjuvant Conditioning of Prostate Cancer Tumor Microenvironment Using a Novel Chemokine-Modulating Regimen
Latest Information Update: 22 Apr 2025
At a glance
- Drugs Rintatolimod (Primary) ; Aspirin; Interferon alpha-2b
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacodynamics
Most Recent Events
- 17 Apr 2025 Status changed from suspended to recruiting.
- 17 Apr 2025 Planned End Date changed from 29 May 2024 to 29 Nov 2026.
- 17 Apr 2025 Planned primary completion date changed from 29 May 2024 to 29 Nov 2026.